NCT00548691View on ClinicalTrials.gov

Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

513

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

July 31, 2009

Conditions
Anemia
Interventions
DRUG

Ferric Carboxymaltose

DRUG

Standard Medical Care (SMC)

Trial Locations (1)

19403

Luitpold Pharmaceuticals, Norristown

Sponsors
All Listed Sponsors
lead

American Regent, Inc.

INDUSTRY